All AbMole products are for research use only, cannot be used for human consumption.
AZ628 is a potent tyrosine protein inhibitor for wild-type CRAF and BRAF V600E with IC50 of 29 and 34 nM, respectively. AZ628 inhibits activities of preactivated wild-type B-Raf with an IC50 of 105, respectively. AZ628 also suppreses activities of a number of tyrosine protein kinases such as VEGFR2, DDR2, Lyn and Flt1. AZ628 also prevents anchorage-dependent and -independent growth, gives rise to cell cycle arrest, and triggers apoptosis in colon and melanoma cell lines harboring B-RafV600E mutation. AZ628 is antiangiogenic based on inhibition of VEGFR2.
Oncogene. 2021 Jun;40(24):4137-4150.
Targeting the p300/NONO axis sensitizes melanoma cells to BRAF inhibitors
AZ628 purchased from AbMole
 |
Source | Cancer Discov (2013). Figure 5. AZ628 |
| Method | Western blotting | |
| Cell Lines | A375 cells | |
| Concentrations | 0.2 μM | |
| Incubation Time | 16 h | |
| Results | In contrast to the aforementioned drug conditions, only minimal resistance (2-fold) was observed to AZ628 |
| Cell Experiment | |
|---|---|
| Cell lines | The human melanoma cell |
| Preparation method | Cells were maintained at 37°C in a humidified atmposphere at 5% CO2 grown in RPMI 1640 supplemented with 10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin and 2nM glutamine. AZ628 resistant M14 clones were maintained in the above-mentioned medium and 2 μM of AZ628, except where otherwise indicated. The BRAF inhibitor AZ628 was synthesized by Astra Zeneca. |
| Concentrations | 2 μM |
| Incubation time | 16 h |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 451.52 |
| Formula | C27H25N5O2 |
| CAS Number | 878739-06-1 |
| Solubility (25°C) | DMSO 70 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Raf Products |
|---|
| GDC-0879
GDC-0879 is a potent and selective B-Raf kinase inhibitor with an EC50 of 0.75 µM. |
| Vemurafenib (PLX4032)
Vemurafenib (PLX4032) is a first-in-class, potent, selective inhibitor of B-Raf that inhibits RAFV600E and C-RAF-1 activity with IC50s of 31 nM and 48 nM, respectively.In addition, Vemurafenib induces autophagy. |
| PLX-4720
PLX-4720 is a selective BRAFV600E inhibitor with the IC50 values of 160 nM and 130 nM for B-Raf and BRK respectively. |
| SB590885
SB590885 is a selective small-molecule inhibitor of the B-Raf kinase and Ki values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively. |
| ZM 336372
ZM 336372 is a potent, selective ATP-competitive inhibitor of c-Raf in vitro (IC50 = 70 nM for inhibition of human c-Raf). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
